This Friday is #WorldPrematurityDay. Let's spotlight the resilience of premature babies and acknowledge the dedicated efforts of medical professionals in neonatal care. Together, we can make a difference for the 15 billion babies born too soon every year. https://t.co/Haw1OdZGLr
This Thursday SIME CEO Povl Verder will present at the @flowwVC Investor Showcase. What is Floww? It’s an all-in-one platform fundraising platform that connects founders, venture capitalists and investors through data-centric networking.
#flowwio#seriesA#medtechinvestment
Thank you to the Department of Business and Trade for inviting SIME CEO, Povl Verder, to pitch to a captive audience of lifesciences investors on the London Eye @LDNTechWeek#LondonTechWeek
The SIME team were honoured meet the prestigious Prof Tsu Fuh Yeh last week @PASMeeting . Prof Yeh presented exciting new data about surfactant and budesonide treatment for neonatal CLD/BPD.
SIME scientific co-founder Prof Henrik Verder and Peter Schousbe, SIME Head of R&D, with our esteemed partners @InspHealthcare and @DrRamanathanUSC at last weeks @PASMeeting in Washington.
We will be sharing exciting new data @PASMeeting this week. In continued preparation for market entry, we will also be meeting with our US clinical & commercial partners as well as exploring new opportunities. Interested in meeting us for a chat? Send us a DM. See you there!
Yesterday our CEO had the honour of meeting @Jeremy_Hunt and life sciences leaders to discuss the future of life science innovation in the UK. Thank you @hmtreasury @scale_space and @imperialcollege for hosting us.
https://t.co/SVqN6bIJ45
Preterm birth & stillbirth rates during COVID-19 lockdown- analysis of 52 million births! Collaborative led by @MeghanAzad published in Nature Human Behaviour. https://t.co/uci8XOP2Nx
Irish contribution from UMHL & INHA. @IrishNeonatal@ULHospitals@UL@MedicineAtUL@RCPI_news
NEW PRESS RELEASE: SIME begins clinical trial validating point-of-care device that rapidly predicts neonatal respiratory disease at birth in the NICU #PressRelease#NICU#respiratory#medicalnews#MEDTECH
https://t.co/aw0ZZpy9cD
Join us in welcoming new #BIAmember@simedx 💡
They are a clinical AI company with a patented point-of-care platform for rapid prediction of respiratory disease in the ICU.
Find out more 👇
https://t.co/GzN0CAzjLc
SIME will be attending the #JPM2023 next week in San Francisco. We will be presenting in-person and online on Monday the 9th at 9:00am PST at the Hilton (Franciscan D - Ballroom Level). Message us for meeting appointments.
#biotech#biotechshowcase#jpm2023
Today is #WorldPrematurityDay2022 - to help raise awareness of the challenges and burden of preterm birth globally we have created an infographic. Please share to highlight the challenges these newborns must overcome to survive & thrive. View infographic: https://t.co/5zxOfOnC9F
.@simedx has announced the successful CE-IVD accreditation of the world’s first Clinical AI Platform for the rapid prediction of severe respiratory disease https://t.co/9Rm4gjM4Et
Our AI device that predicts acute respiratory disease has received a CE Mark - taking us one step closer to changing the standard of care for millions of babies worldwide. Our point-of-care device is now available for investigational use in the NICU. https://t.co/JckBRWS01n
SIME STRENGTHENS BOARD TO PREPARE FOR COMMERCIALISATION
Morten Henneveld, a life science executive with decades of commercial and operations experience, joins SIME board as company prepares for Clinical AI Platform product launch in 2023.
https://t.co/TFLeSoBFAq
That's a wrap!👏
#FIME2022 is over, but we want more #innovations, networking and business deals! 🚀
✔️ 700+ exhibitors
✔️ 125+ countries
✔️ 12,650+ attendees
✔️ 4 conferences
Special thanks to all the #SMEs who represented the #EUeic at the 🇪🇺 Pavilion. Until next time 👋